Health CareHealth Care Equipment & Services
  • Price (USD)62.94
  • Today's Change-0.150 / -0.24%
  • Shares traded2.24m
  • 1 Year change+15.83%
  • Beta0.4531
Data delayed at least 15 minutes, as of Sep 23 2021 00:00 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Centene Corporation is a multi-national healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It also provides education and outreach programs to inform and assist members in accessing appropriate healthcare services. It operates through two segments: Managed Care and Specialty Services. The Managed Care segment provides health plan coverage to individuals through government subsidized and commercial programs. Its Specialty Services segment includes companies offering diversified healthcare services and products to its Managed Care segment and other external customers. It provides a range of healthcare products and services, primarily through Medicaid, Medicare and commercial products.

  • Revenue in USD (TTM)118.39bn
  • Net income in USD720.00m
  • Incorporated2001
  • Employees71.30k
  • Location
    Centene Corp7700 Forsyth BlvdST. LOUIS 63105-1807United StatesUSA
  • Phone+1 (314) 725-4477
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centene.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CNC:NYQ since
Circle Health LtdDeal completed07 Jul 202107 Jul 2021Deal completed-14.50%967.12m
Magellan Health IncAnnounced04 Jan 202104 Jan 2021Announced4.85%2.49bn
PANTHERx Rare LLCDeal completed15 Dec 202015 Dec 2020Deal completed5.37%--
Apixio IncAnnounced09 Nov 202009 Nov 2020Announced-7.35%--
Data delayed at least 15 minutes, as of Sep 23 2021 00:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Chemed Corporation2.12bn303.40m7.44bn15.54k25.418.5120.543.5118.6218.62130.3055.591.59183.5316.58136,464.4022.6818.1929.0522.8335.6431.5214.3010.430.9786536.220.009.897.276.1545.2623.715.927.49
Encompass Health Corp4.91bn383.00m7.46bn43.00k19.524.2310.131.523.843.8449.0117.710.7482--8.31114,102.307.427.069.028.8195.8096.139.928.81--4.570.589534.830.85568.31-20.899.3221.144.94
Tenet Healthcare Corp19.21bn434.00m7.77bn85.80k18.7429.724.290.40453.873.87177.622.440.72739.337.08223,857.803.481.245.001.7482.9783.644.781.591.392.510.8261---4.54-1.09264.20---8.50--
Agilon Health Inc-100.00bn-100.00bn11.07bn548.00--9.62----------2.94----------------------------0.0414--53.36--44.77------
Universal Health Services, Inc.12.21bn1.08bn12.07bn68.10k11.501.867.490.988812.6412.64142.7177.950.9784--7.57179,300.208.707.3110.578.62----8.907.541.1016.160.35334.681.595.0315.776.7014.128.45
Oak Street Health Inc1.12bn-313.04m12.10bn3.20k--55.57--10.84-1.43-1.435.080.90410.9887--3.55348,874.70-27.83---40.99--5.67---28.14-----63.060.8029--58.60---56.82------
Davita Inc11.57bn883.30m12.56bn67.00k15.629.917.101.097.677.5099.5012.100.623274.396.22172,625.406.
Molina Healthcare, Inc.23.58bn632.00m16.31bn10.50k26.036.8421.960.691910.7310.73398.6140.862.56--13.722,245,524.006.874.5114.1310.7716.0315.902.681.84--8.900.49810.0015.416.50-8.6836.31-10.93--
Quest Diagnostics Inc11.06bn2.24bn18.86bn40.00k9.,450.0017.457.6620.318.8541.7437.2920.4010.911.2618.290.399931.2822.154.7270.6615.089.718.50
Teladoc Health Inc1.63bn-763.32m22.07bn4.40k--1.38--13.55-5.66-5.6612.52100.340.1627--12.71370,215.20-7.62-6.58-7.78-6.7867.2267.06-46.86-36.033.79-6.710.0711--97.7169.85-390.71--27.21--
Laboratory Corp. of America Holdings16.39bn2.88bn28.36bn72.40k10.042.787.901.7329.2929.29166.76105.950.856526.356.50226,355.0015.055.7617.716.6538.6130.5517.588.351.9822.040.34980.0020.9810.0088.8928.888.33--
Centene Corp118.39bn720.00m36.78bn71.30k51.991.4217.800.31071.211.21202.3544.441.69----1,660,393.001.013.45--------0.5981.56--4.500.39120.0048.8737.3236.8738.4042.10--
Humana Inc80.45bn2.48bn51.50bn48.70k21.183.4716.910.640118.9218.92613.86115.512.10----1,651,951.006.247.96--------2.973.55--13.390.332911.8018.907.2824.3821.4213.0121.75
Data as of Sep 23 2021. Currency figures normalised to Centene Corp's reporting currency: US Dollar USD

Institutional shareholders

46.05%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202159.37m10.18%
Capital Research & Management Co. (World Investors)as of 30 Jun 202144.76m7.68%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 202129.51m5.06%
Fidelity Management & Research Co. LLCas of 30 Jun 202126.46m4.54%
BlackRock Fund Advisorsas of 30 Jun 202125.32m4.34%
SSgA Funds Management, Inc.as of 30 Jun 202123.48m4.03%
Capital Research & Management Co. (International Investors)as of 30 Jun 202120.06m3.44%
Wellington Management Co. LLPas of 30 Jun 202118.99m3.26%
Viking Global Investors LPas of 30 Jun 202111.20m1.92%
Boston Partners Global Investors, Inc.as of 30 Jun 20219.36m1.61%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.